[Lomefloxacin in the treatment and prevention of urogenital infection].
A new antibiotic from fluoroquinolone series maxaquine (lomefloxacin) made in USA (Searle [correction of Surl]) has been tried in the treatment of urogenital infection (chronic cystitis, prostatitis, pyelonephritis, acute epididymitis, chlamydial urethroprostatitis) as well as to warrant antibacterial preparation before extracorporeal lithotripsy. The duration of the treatment course (3-28 days) was oriented to nosological form. The 24-h dose ranged from 400 to 800 mg. Side effects manifested with dyspepsia in 4 patients, worsening of memory in 2 patients. Photosensitization did not occur. Maxaquine clinical efficacy is similar to aminoglycosides and is superior to cephalosporins of the third generation. As for fluoroquinolone antibiotics, maxaquine can be compared to cyprofloxacine. The drug proved effective against urethroprostatitis and urethrocystitis of chlamydial origin. The responses to maxaquine favour its application in hospitals as second-line drug, whereas outpatiently it can be used for short-term empiric therapy.
Perepanova
T S
TS
Darenkov
A F
AF
Kotliarova
G A
GA
Kondrat'eva
E M
EM
Siniukhin
V N
VN
Beshliev
D A
DA
D000208:Acute Disease; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002690:Chlamydia Infections / Q000188:drug therapy*; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D052776:Female Urogenital Diseases / Q000188:drug therapy*; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases; D015363:Quinolones / Q000008:administration & dosage* / Q000009:adverse effects; D013607:Tablets; D013997:Time Factors
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D013607:Tablets; C053091:lomefloxacin